WF 23 | 146877-60-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: WF 23
• 英文别名: 8-methyl-3β-(2-naphthyl)-2β-propanoyl-8-azabicyclo<3.2.1>octane；WF-23；1-[(1R,2S,3S,5S)-8-methyl-3-naphthalen-2-yl-8-azabicyclo[3.2.1]octan-2-yl]propan-1-one
• CAS: 146877-60-3
• 化学式: C₂₁H₂₅NO
• 分子量: 307.436
• InChiKey: WJVLEIDMFWNIAA-PXCRPINLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  5-己烯-3-酮 在 RhCl(PPh₃)3 rhodium(II) octanoate 、 copper bromide-dimethyl sulfide 、 4-乙酰氨基苯磺酰叠氮 、 氢气 、 sodium cyanoborohydride 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三氟乙酸 作用下， 以 乙醚 、 乙醇 、 正己烷 、 二氯甲烷 、 水 、 乙腈 为溶剂， 25.0 ℃ 、310.27 kPa 条件下， 反应 18.25h， 生成 WF 23
  参考文献：
  名称：

  Synthesis of 2.beta.-Acyl-3.beta.-aryl-8-azabicyclo[3.2.1]octanes and Their Binding Affinities at Dopamine and Serotonin Transport Sites in Rat Striatum and Frontal Cortex

  摘要：

  A novel entry to tropane analogs of cocaine was developed on the basis of the reaction of rhodium-stabilized vinylcarbenoids with pyrroles. These analogs were tested:in binding to dopamine and serotonin (5-HT) transporters in:membranes from rat striatum and frontal cortex. In all the analogs, the aryl group at the 3-position was directly bound to the tropane ring (as in WIN-35,428), and methyl or ethyl ketone moieties were present at the a-position instead of the typical ester group. The series of analogs containing a 2-naphthyl group at the 3-position were most potent, with K-i values < 1 nM in binding to both dopamine and 5-HT transporters. Although the unsubstituted 2-naphthyl analog was nonselective at dopamine and 5-HT transport sites, other compounds:were selective for either site. In general, compounds with relatively small substituents on the aromatic moiety (such as p-methyl or p-fluoro) were relatively selective for the dopamine transporters, while a p-isopropylphenyl derivative was selective:for the 5-HT transport sites. This latter compound represents the first N-methyltropane derivative specific for 5-HT transporters. Resolution of two of the most significant analogs was achieved by HPLC on a chiral stationary phase; the active enantiomer of a 2-naphthyl analog exhibited K-i values of <0.1 nM at both dopamine and 5-HT transporter sites.

  DOI：

  10.1021/jm00035a005

文献信息

• NMN AND DERIVATIVES FOR ITS USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM
  申请人：Nuvamid SA

  公开号：EP4079311A1

  公开（公告）日：2022-10-26

  The invention relates to compounds of formula (I) and/or of formula (Ia) for the prevention and/or treatment of depression and/or anxiety related to a Parkinsonism such as an alpha-synucleinopathy as well as compositions and kit of parts comprising the same.

  本发明涉及用于预防和/或治疗与帕金森病（如α-突触核蛋白病）相关的抑郁和/或焦虑症的式(I)和/或式(Ia)化合物，以及包含这些化合物的组合物和试剂盒。
• Medical fluid, a method of treatment and use of the fluid
  申请人：XVIVO PERFUSION AB

  公开号：US10271540B2

  公开（公告）日：2019-04-30

  A medical fluid for a harvested organ, tissue or part thereof, for evaluation and/or preservation. The fluid includes cocaine or a stimulating analog thereof; noradrenaline; and/or adrenaline. In addition, the fluid includes an oncotic agent, such as dextran; hormones, such as thyroxin; triiodotyronine; cortisone, insulin; and electrolytes and optionally nutrients in substantially physiological concentrations in a physiologically acceptable medium. In addition, the medical fluid further includes albumin in a concentration not exceeding 5.0%, and an oxygen carrier, such as erythrocytes. Further components may be dopamine; hydrocortisone; methylprednisolone; and a vasopressor agent, such as desmopressin. The cocaine; adrenaline; and noradrenaline are present in concentrations of each about 0.010 μM to 0.100 μM, for example in a ratio of 1:1:1.

  一种用于评估和/或保存摘取的器官、组织或其部分的医用液。该液体包括可卡因或其刺激类似物、去甲肾上腺素和/或肾上腺素。此外，该药液还包括一种抗肿瘤剂，如右旋糖酐；激素，如甲状腺素；三碘酪氨酸；可的松、胰岛素；以及电解质和生理上可接受的介质中基本为生理浓度的营养物质。此外，医用流体还包括浓度不超过 5.0% 的白蛋白和氧载体，如红细胞。其他成分可以是多巴胺、氢化可的松、甲基强的松龙和血管加压剂，如去氨加压素。可卡因、肾上腺素和去甲肾上腺素的浓度各约为 0.010 μM 至 0.100 μM，例如比例为 1:1:1。
• Treatment of dermatological conditions via neuromodulation
  申请人：Palo Alto Investors

  公开号：US11383084B2

  公开（公告）日：2022-07-12

  Methods for treating a subject for a dermatological condition are provided. Aspects of the invention include administering an effective amount of a neuromodulatory agent to a subject to treat the subject for the dermatological condition. Also provided are compositions, kits and systems for practicing the subject methods.

  本发明提供了治疗受试者皮肤病的方法。本发明的各个方面包括向受试者施用有效量的神经调节剂，以治疗受试者的皮肤病。本发明还提供了用于实施上述方法的组合物、试剂盒和系统。
• A COMPOSITION COMPRISING NOR-ADRENALINE AND A NET INHIBITOR FOR ADMINISTERING TO A BRAIN-DEAD, HEART-BEATING POTENTIAL ORGAN DONOR.
  申请人：Vivoline Medical AB

  公开号：EP2384112A1

  公开（公告）日：2011-11-09
• A MEDICAL FLUID, A METHOD OF TREATMENT AND USE OF THE FLUID
  申请人：XVIVO Perfusion AB

  公开号：EP2568805B1

  公开（公告）日：2019-05-01